busulfan + cyclophosphamide + fludarabine

This is a combination chemotherapy regimen consisting of three small molecule alkylating and antimetabolite agents—busulfan, cyclophosphamide, and fludarabine. It is primarily used as a conditioning protocol prior to allogeneic hematopoietic stem cell transplantation (HSCT), including haploidentical transplants. The combination works synergistically to ablate bone marrow and suppress the immune system in preparation for engraftment. Busulfan and cyclophosphamide are both alkylating agents that cause DNA crosslinking and cell death; fludarabine is a purine analog antimetabolite that inhibits DNA synthesis by interfering with DNA polymerase and ribonucleotide reductase activity. This regimen has been studied for use in various hematologic malignancies (such as acute myeloid leukemia) as well as non-malignant disorders like adrenoleukodystrophy or mucopolysaccharidoses[1][4].

Other names

busulfancyclophosphamidefludarabineBFC conditioning regimen